Literature DB >> 13273342

Clotting factor X; physiologic and physico-chemical properties.

F DUCKERT, P FLUCKIGER, M MATTER, F KOLLER.   

Abstract

Keywords:  BLOOD COAGULATION

Mesh:

Substances:

Year:  1955        PMID: 13273342     DOI: 10.3181/00379727-90-21927

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


× No keyword cloud information.
  10 in total

1.  [ACTIVATION OF BLOOD COAGULATION BY A BACTERIAL ENDOTOXIN IN PERSONS UNDER COUMARIN THERAPY].

Authors:  M H HOERDER; R MANRIQUE
Journal:  Klin Wochenschr       Date:  1965-04-01

Review 2.  [THE STUART-PROWER FACTOR: ITS COAGULATION PHYSIOLOGY AND CLINICAL SIGNIFICANCE].

Authors:  V HIEMEYER; M H HOERDER
Journal:  Klin Wochenschr       Date:  1964-11-15

3.  Influence of coumarin treatment on plasma thromboplastin formation and heparin tolerance.

Authors:  R HOLEMANS; M VERSTRAETE
Journal:  Blut       Date:  1962-03

4.  Levels of blood-coagulation factors during anticoagulant therapy with phenindione.

Authors:  K W DENSON
Journal:  Br Med J       Date:  1961-04-29

5.  [Differential diagnosis of congenital Stuart factor deficiency].

Authors:  M H HORDER
Journal:  Klin Wochenschr       Date:  1959-04-15

6.  Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA, proconvertin, factor VII) deficiency.

Authors:  C HOUGIE; E M BARROW; J B GRAHAM
Journal:  J Clin Invest       Date:  1957-03       Impact factor: 14.808

7.  [Familial deficiency of factor X].

Authors:  J OEHME; G SCHWICK; H E SCHULTZE
Journal:  Klin Wochenschr       Date:  1958-06-01

8.  Studies on the clot-promoting activity of glass.

Authors:  A DE VRIES; E SHAFRIR
Journal:  J Clin Invest       Date:  1956-11       Impact factor: 14.808

9.  Inherited Factor X (Stuart-Prower Factor) deficiency and its management.

Authors:  T Chatterjee; J Philip; Velu Nair; R S Mallhi; Hemant Sharma; P Ganguly; A K Biswas
Journal:  Med J Armed Forces India       Date:  2014-04-03

10.  Platelet factor 3 in normal subjects and patients with renal failure.

Authors:  S F Rabiner; O Hrodek
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.